U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.14
    +0.50 (+1.10%)
     
  • Gold

    1,841.30
    +0.20 (+0.01%)
     
  • Silver

    24.30
    +0.16 (+0.65%)
     
  • EUR/USD

    1.2124
    -0.0025 (-0.2061%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3437
    -0.0016 (-0.1196%)
     
  • USD/JPY

    104.1870
    +0.3270 (+0.3148%)
     
  • BTC-USD

    18,811.24
    -146.77 (-0.77%)
     
  • CMC Crypto 200

    368.29
    -10.95 (-2.89%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Senseonics Holdings, Inc. Schedules Third Quarter 2020 Earnings Release and Conference Call for November 9, 2020 at 4:30 p.m. Eastern Time

·1 min read

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2020 financial results after market close on Monday, November 9, 2020.

Management will hold a conference call to review the company’s third quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 1-888-243-4451 (US/Canada) or 1-412-542-4135 (International), passcode 4128608, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM Systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028006071/en/

Contacts

Senseonics Investor Contact
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
investors@senseonics.com